Coya Therapeutics, Inc. (COYA) AI Stock Analysis

• Market Cap: $103.79M
• Dividend Yield: N/A
• Average Volume (3M): 266.35K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.19
• Revenue Growth: -58.26%
• EPS Growth: -53.20%
• Country: US
• Employees: 8
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 20,924,456
• 10 Day Avg. Volume: 216,274
• 30 Day Avg. Volume: 266,345
• PEG Ratio: -0.24
• Price to Book (P/B): 2.21
• Price to Sales (P/S): 24.57
• P/FCF Ratio: -8.49
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: 13.61
• Enterprise Value/Gross Profit: -17.08
• Enterprise Value/Ebitda: -2.72
• 1Y Price Target: $17.00
• Price Target Upside: 242.74% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -1.49
• Revenue Forecast (FY): $1.92M

• Rating: 45 Neutral
• Price Target: $4.50 ▼(-9.27% Downside)
• Action: Reiterated Date: 01/30/26
• Date: Action: Reiterated 01/30/26

Overall score is weighed down primarily by weak financial performance (large losses and very heavy reported TTM cash burn) and a bearish technical setup (below major moving averages with negative MACD). Offsetting factors include positive recent corporate developments that improve funding visibility (cash runway into 2H 2027 and new financing) and some revenue traction, but valuation remains difficult to assess given negative earnings and no dividend data.

Positive Factors

Strategic Investor Financing

A strategic $11.1M equity placement led by Dr. Reddy’s (plus Greenlight) is durable validation of the COYA 302 program and strengthens the company’s strategic collaborator ties. Partner capital and alignment reduce execution risk for manufacturing scale-up and commercial readiness over the next 2–6 months.

Cash Runway Into 2H 2027

A $46.8M cash balance and guidance of runway into 2H 2027 provide the company with the liquidity to advance key clinical programs and manufacturing scale-up through upcoming catalysts (e.g., ALSTARS topline). This materially reduces near-term financing pressure and supports program continuity over the medium term.

Regulatory and Clinical Progress

FDA IND acceptance and initiation of the ALSTARS Phase 2 trial represent structural de-risking of COYA 302’s development pathway. Moving into a Phase 2 study and achieving associated milestones increases the probability of further partner payments and creates clear near-term clinical catalysts with lasting strategic implications.

Negative Factors

Extremely Large TTM Cash Burn

An outsized trailing-twelve-month cash burn (~-$2.84B) is a severe structural weakness: it elevates the likelihood of near-term dilutive financings, constrains discretionary R&D and commercialization investment, and forces dependence on milestone or partner funding to sustain operations beyond current runway.

Persistent Operating Losses

Consistent negative gross profit and sizable operating losses show the business remains investment-stage with limited earnings power. Over a multi-month horizon this reduces margin sustainability, raises ongoing funding needs, and limits ability to self-fund development or commercial launches without external capital.

Revenue Model Dependency on Partners

The company’s revenue model is structurally dependent on collaborations, milestone payments, and future royalties rather than product sales. This creates lumpy, execution-dependent cash flows, limits predictable revenue generation, and increases reliance on partner alignment to fund long-term commercialization.

Coya Therapeutics, Inc. Business Overview & Revenue Model

Company Description

Coya Therapeutics, Inc., a clinical-stage biotechnology company, develops proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a Treg-enhancing biologic for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous and/or intravenous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an allogeneic Treg exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company was incorporated in 2020 and is headquartered in Houston, Texas.

How the Company Makes Money

Coya Therapeutics, Inc. generates revenue through the development and commercialization of its proprietary therapies. The company primarily earns money by advancing its drug candidates through clinical trials, seeking regulatory approval, and ultimately bringing successful treatments to market. Revenue streams may include product sales, licensing agreements, and strategic partnerships with other biotechnology and pharmaceutical companies. These partnerships often involve collaborative research and development efforts, as well as milestone and royalty payments based on the successful commercialization of joint projects. Additionally, Coya may receive funding from grants or government programs aimed at supporting innovative medical research.

Coya Therapeutics, Inc. Financial Statement Overview

Summary

Early revenue traction is offset by development-stage fundamentals: negative gross profit, sizable operating and net losses (EBIT about -$20.1M; net income about -$18.4M), and persistently negative cash flow with an extremely large TTM cash burn (about -$2.84B), which elevates funding and dilution risk. Balance sheet is a relative bright spot with zero debt and still-positive equity (~$27.3M), but equity has declined and returns remain materially negative.

Income Statement

Revenue has turned on and scaled sharply in TTM (Trailing-Twelve-Months) (up ~842%), but profitability remains weak: gross profit is negative and operating losses are large (EBIT about -$20.1M; net income about -$18.4M). Annual results show revenue volatility (down in 2024 vs. 2023) and consistently negative net results, indicating the business is still heavily investment-driven with limited earnings power today.

Balance Sheet

The balance sheet is currently conservatively levered with zero total debt in 2023–TTM (Trailing-Twelve-Months) and positive equity (TTM equity ~$27.3M; assets ~$32.0M), which supports financial flexibility. However, equity has declined from 2024 (~$39.6M) to TTM, and returns on equity are materially negative, reflecting ongoing losses; the company also previously had negative equity and meaningful debt in 2022, highlighting historical balance-sheet stress.

Cash Flow

Cash generation is the key weak spot: operating cash flow and free cash flow are negative across periods, and TTM (Trailing-Twelve-Months) cash burn is extremely large (about -$2.84B), far worse than prior years (~-$10–11M in 2023–2024). While free cash flow has occasionally improved year-over-year, the persistent and recently outsized burn meaningfully raises funding and dilution risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	3.99M	3.55M	6.00M	0.00	0.00	0.00
Gross Profit	-3.18M	-8.31M	500.68K	-4.41M	0.00	0.00
EBITDA	-19.94M	-17.20M	-7.33M	-9.26M	-4.85M	0.00
Net Income	-18.43M	-14.88M	-7.99M	-12.24M	-4.89M	-1.10M
Balance Sheet
Total Assets	32.04M	44.35M	41.26M	8.40M	4.79M	8.75M
Cash, Cash Equivalents and Short-Term Investments	28.13M	38.34M	32.63M	5.93M	4.34M	8.72M
Total Debt	0.00	0.00	0.00	12.97M	0.00	0.00
Total Liabilities	4.76M	4.77M	5.63M	16.79M	1.15M	447.12K
Stockholders Equity	27.28M	39.58M	35.64M	-8.39M	3.64M	8.30M
Cash Flow
Free Cash Flow	-12.14M	-10.29M	-11.19M	-7.24M	-4.04M	-391.27K
Operating Cash Flow	-12.14M	-10.29M	-11.19M	-7.24M	-3.90M	-391.27K
Investing Cash Flow	-516.00K	-25.00K	-543.19K	-525.00K	-136.80K	0.00
Financing Cash Flow	9.73M	16.03M	38.43M	9.36M	-340.58K	9.11M

Coya Therapeutics, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 4.96
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For COYA, the sentiment is Positive. The current price of 4.96 is above the 20-day moving average (MA) of 4.80, above the 50-day MA of 4.96, and below the 200-day MA of 5.77, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 53.05 is Neutral, neither overbought nor oversold. The STOCH value of 82.49 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for COYA.

Coya Therapeutics, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STTK	53 Neutral	$248.06M	-3.84	-57.84%	―	-84.46%	33.32%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SPRO	48 Neutral	$122.26M	-2.73	-95.29%	―	-67.38%	-1076.54%
INO	47 Neutral	$124.35M	-0.70	-328.45%	―	-10.36%	42.36%
NKTX	47 Neutral	$191.78M	-1.94	-26.69%	―	―	25.84%
ANVS	46 Neutral	$71.03M	-1.81	-246.14%	―	―	62.84%
COYA	45 Neutral	$103.79M	-4.50	-62.18%	―	-58.26%	-53.20%

Coya Therapeutics, Inc. Corporate Events

Coya Therapeutics Announces Strategic Private Placement Financing

On January 29, 2026, Coya Therapeutics, Inc. entered into a securities purchase agreement with Dr. Reddy’s Laboratories and Greenlight Capital for a private placement of 2,522,727 common shares at $4.40 per share, expected to close on or about January 30, 2026 and raise roughly $11.1 million in gross proceeds. The financing, led by a $10 million investment from Dr. Reddy’s, a subsidiary of Coya’s current strategic collaborator, and $1.1 million from existing shareholder Greenlight Capital, is structured as an unregistered offering under Section 4(a)(2), with Coya committing to register the resale of the shares after closing; the company plans to use the funds to transfer and scale up manufacturing of low-dose IL‑2 to support commercial readiness of COYA 302, while reiterating that the additional capital should accelerate its commercial plans without altering its cash runway guidance into the second half of 2027 and beyond the projected topline readout of its ALSTARS ALS trial.

The most recent analyst rating on (COYA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Coya Therapeutics Reports Strong Cash Position and Runway

On January 20, 2026, Coya Therapeutics, Inc. informed stockholders that its unaudited cash balance as of December 31, 2025 stood at $46.8 million, providing a projected cash runway into the second half of 2027 and supporting continued operations and development activities. The company also noted that it expects to deliver topline data from its ongoing ALSTARS Phase 2 trial in the first quarter of 2027, a milestone that could be pivotal for its clinical progress and of particular interest to investors and other stakeholders tracking its ALS program.

The most recent analyst rating on (COYA) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data

On January 8, 2026, Coya Therapeutics, Inc. reported positive results from an investigator-initiated, open-label proof-of-concept study evaluating a combination of low-dose IL-2 and CTLA4-Ig in nine patients with frontotemporal dementia over six months at the Houston Methodist Neurological Institute. The regimen, consisting of subcutaneous CTLA4-Ig and a five-day course of low-dose IL-2 every four weeks for 22 weeks, showed a favorable safety profile with only mild injection-site erythema and no serious adverse events, while demonstrating significantly increased Treg suppressive function, Treg percentages, and associated biomarkers (CD25 and FOXP3) from two weeks through 22 weeks. Cognitive assessments using the Montreal Cognitive Assessment and CDR-FTLD scales showed no significant decline from baseline to week 22, suggesting potential disease stabilization in this small cohort and supporting further exploration of Coya’s Treg-targeted approach in FTD.

The most recent analyst rating on (COYA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Coya Therapeutics Receives $4.2M Milestone Payment

On December 16, 2025, Coya Therapeutics, Inc. received a $4.2 million milestone payment under a Development and License Agreement with Dr. Reddy’s Laboratories. This payment was triggered by the dosing of the first patient in the company’s ALSTARS trial, which aims to evaluate COYA 302 for treating ALS. The milestone highlights progress in their ALS treatment efforts and reflects positively on the collaboration between Coya and Dr. Reddy’s Laboratories, marking a significant step forward in advancing its clinical operations.

The most recent analyst rating on (COYA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.

Coya Therapeutics Reports Q3 2025 Financial Results

Coya Therapeutics announced its third-quarter financial results for 2025, highlighting significant corporate developments. The company received FDA acceptance for its Investigational New Drug (IND) application for COYA 302, aimed at treating Amyotrophic Lateral Sclerosis (ALS), and launched the ALSTARS Trial, a Phase 2 study for the same. Additionally, they reported promising preclinical results for COYA 303 and completed patient enrollment for a study on Frontotemporal Dementia (FTD). Financially, Coya closed a $23 million public offering, extending its cash runway into the second half of 2027. The company reported a net loss of $2.1 million for the quarter, a reduction from the previous year’s $4 million loss, with increased revenues and expenses attributed to the advancement of their clinical programs.

The most recent analyst rating on (COYA) stock is a Buy with a $17.00 price target. To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock, see the COYA Stock Forecast page.